TITLE

Use of intravitreal anti-VEGF: Retinopathy of prematurity surgeons' in Hamlet's dilemma?

AUTHOR(S)
Azad, Rajvardhan
PUB. DATE
November 2011
SOURCE
Indian Journal of Ophthalmology;Nov2011, Vol. 59 Issue 6, p421
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on the usage of intravitreal anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinopathy of prematurity (ROP). As per him, it is difficult for pediatric ophthalmologists and retinal surgeons to understand the utility of such drugs in ROP, particularly, in the area of systematic safety of the drugs. He opines that there should be proper investigation through scientific protocols and developmental outcomes before using the VEGF agents in ROP.
ACCESSION #
67520105

 

Related Articles

  • Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Tahija, Sjakon G.; Hersetyati, Rini; Lam, Geoffrey C.; Kusaka, Shunji; McMenamin, Paul G. // British Journal of Ophthalmology;Apr2014, Vol. 98 Issue 4, p507 

    Aim To evaluate vascularisation of the peripheral retina using fluorescein angiography (FA) digital recordings of infants who had been treated with intravitreal bevacizumab (IVB) as sole therapy for zone I and posterior zone II retinopathy of prematurity (ROP). Methods A retrospective evaluation...

  • IN THE JOURNALS. Hasson, Matt // Ocular Surgery News;6/25/2014, Vol. 32 Issue 12, p22 

    This section offers news briefs on ophthalmology. No distinct advantage was exhibited by corneal debridement in treating corneal lesions and microsporidial keratoconjunctivitis. A study shows that large-angle infantile esotropia have been reduced by three-muscle surgery. A study shows that a...

  • Anti-VEGFs may be viable option in treating retinopathy of prematurity. Cimberle, Michela // Ocular Surgery News;9/10/2009, Vol. 27 Issue 17, p29 

    The article reports on the claim of Georges Caputo of Fondation Rothschild about the potential of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of retinopathy of prematurity (ROP). Caputo noted that VEGF is involved in the metabolic and inflammatory processes that lead...

  • Treatment-requiring ROP: Improved vascular patterns. Charters, Lynda // Ophthalmology Times;May2015, Vol. 40 Issue 8, p16 

    The article discusses a prospective case series study on the improvement of vascular patterns for retinopathy of prematurity (ROP) treatment. Topics covered include patients in Mexico City with ROP at stage 3 threshold and pre-threshold and performance of fluorescein angiography before...

  • Anti-VEGF therapy may have a role in the treatment of ROP.  // Ocular Surgery News;6/10/2009, Vol. 27 Issue 11, p22 

    The article focuses on the possible role of anti-vascular endothelial growth factors (VEGF) therapy in treating retinopathy of prematurity (ROP). According to Georges Caputo of Foundation Rotschild in Paris, France, VEGF is involved in forming subretinal neovascularization, which then leads to...

  • Update on Anti-VEGF Monotherapy for ROP. Recchia, Franco M.; Capone Jr., Antonio // Review of Ophthalmology;Aug2011, Vol. 18 Issue 8, p56 

    The article offers updates in the use of anti-Vascular Endothelial Growth Factor (VEGF) treatment for retinopathy of prematurity (ROP). ROP is characterized by oxygen-induced attenuation of normal retinal vascularization following hypoxia-induced vasoproliferation. It provides an overview of the...

  • Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo. BANCALARI M., ALDO; SCHADE Y., RICARDO; PEÑA Z., RUBÉN; PAVEZ P., NICOLÁS // Revista Chilena de Pediatría;may/jun2013, Vol. 84 Issue 3, p300 

    Introduction: Standard treatment of threshold Retinopathy of Prematurity (ROP) is laser photocoagulation (LPC). Recently, bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor has been used with positive results. Objective: To communicate the response to treatment with bevacizumab...

  • Bevacizumab in the Treatment of ROP. Neutze, Kimberly A.; Fecarotta, Christopher M. // Review of Ophthalmology;Apr2013, Vol. 20 Issue 4, p90 

    The article discusses the use of bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF), to treat retinopathy of prematurity (ROP) and its side effects. It says that the study by Wei-Chi Wu and colleagues shows that bevacizumab can be effective in treating ROP but complications...

  • A Systematic Review and Meta-Analysis on the Safety of Vascular Endothelial Growth Factor (VEGF) Inhibitors for the Treatment of Retinopathy of Prematurity. Pertl, Laura; Steinwender, Gernot; Mayer, Christoph; Hausberger, Silke; Pöschl, Eva-Maria; Wackernagel, Werner; Wedrich, Andreas; El-Shabrawi, Yosuf; Haas, Anton // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Introduction: Laser photocoagulation is the current gold standard treatment for proliferative retinopathy of prematurity (ROP). However, it permanently reduces the visual field and might induce myopia. Vascular endothelial growth factor (VEGF) inhibitors for the treatment of ROP may enable...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics